Railways PYQCBT 1 2026General Knowledge & Current AffairsScience, Technology & Space

RRB NTPC · Question 34

Which indigenous CAR T-cell therapy, launched in 2025, marked a historic milestone in India’s cancer treatment and biotechnology ecosystem?

  1. OncoShakti indigenous gene-based cancer therapy

  2. NexCAR19 indigenous CAR T-cell therapy

  3. IndiGene CAR T-cell oncology therapy

  4. BharatCAR advanced cellular immunotherapy

Show answer & explanationShow explanation

Answer: (B) NexCAR19 indigenous CAR T-cell therapy

Explanation

• NexCAR19 is India's landmark indigenous CAR T-cell cancer therapy. • CAR (Chimeric Antigen Receptor) T-cell therapy genetically engineers a patient's T-cells to target cancer cells. Related Facts: • NexCAR19 (Actalycabtagene autoleucel) is India's first indigenous CAR T-cell therapy, developed jointly by IIT Bombay, Tata Memorial Centre, and ImmunoACT. • It targets the CD19 protein in patients with relapsed or refractory B-cell lymphomas and acute lymphoblastic leukemia. • NexCAR19 reduced treatment costs to around ₹30–40 lakh compared to ₹3–4 crore for imported CAR T-cell therapies. Correct Answer: (b) NexCAR19 indigenous CAR T-cell therapy

Diagram explaining the answer